BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 31367798)

  • 1. Selecting Adjuvant Treatment for Endometrial Carcinoma Using Molecular Risk Factors.
    Wortman BG; Nout RA; Bosse T; Creutzberg CL
    Curr Oncol Rep; 2019 Jul; 21(9):83. PubMed ID: 31367798
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incorporation of molecular characteristics into endometrial cancer management.
    Vermij L; Smit V; Nout R; Bosse T
    Histopathology; 2020 Jan; 76(1):52-63. PubMed ID: 31846532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estimated intermediate risk endometrial cancer: debate and new perspectives on therapy individualization and prognosis establishment starting from a peculiar case.
    Gizzo S; Fabris A; Litta P; Saccardi C
    Int J Clin Exp Pathol; 2014; 7(5):2664-9. PubMed ID: 24966983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant therapy for early endometrial cancer - who benefits the most from a radiation therapy?
    Michalak M; Warenczak Florczak Z; Staszewska-Nowak A; Roszak A
    Ginekol Pol; 2020; 91(1):6-12. PubMed ID: 32039461
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinicopathological and molecular characterisation of 'multiple-classifier' endometrial carcinomas.
    León-Castillo A; Gilvazquez E; Nout R; Smit VT; McAlpine JN; McConechy M; Kommoss S; Brucker SY; Carlson JW; Epstein E; Rau TT; Soslow RA; Ganesan R; Matias-Guiu X; Oliva E; Harrison BT; Church DN; Gilks CB; Bosse T
    J Pathol; 2020 Mar; 250(3):312-322. PubMed ID: 31829447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A multi-institutional analysis of sequential versus 'sandwich' adjuvant chemotherapy and radiotherapy for stage IIIC endometrial carcinoma.
    Onal C; Sari SY; Yildirim BA; Yavas G; Gultekin M; Guler OC; Akyurek S; Yildiz F
    J Gynecol Oncol; 2019 May; 30(3):e28. PubMed ID: 30887753
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Compliance with adjuvant treatment guidelines in endometrial cancer: room for improvement in high risk patients.
    Eggink FA; Mom CH; Boll D; Ezendam NPM; Kruitwagen RFPM; Pijnenborg JMA; van der Aa MA; Nijman HW
    Gynecol Oncol; 2017 Aug; 146(2):380-385. PubMed ID: 28552255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of different adjuvant treatment approaches on survival in stage III endometrial cancer: A population-based study.
    van Weelden WJ; Reijnen C; Eggink FA; Boll D; Ottevanger PB; van den Berg HA; van der Aa MA; Pijnenborg JMA
    Eur J Cancer; 2020 Jul; 133():104-111. PubMed ID: 32454416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer.
    van den Heerik ASVM; Horeweg N; Nout RA; Lutgens LCHW; van der Steen-Banasik EM; Westerveld GH; van den Berg HA; Slot A; Koppe FLA; Kommoss S; Mens JWM; Nowee ME; Bijmolt S; Cibula D; Stam TC; Jurgenliemk-Schulz IM; Snyers A; Hamann M; Zwanenburg AG; Coen VLMA; Vandecasteele K; Gillham C; Chargari C; Verhoeven-Adema KW; Putter H; van den Hout WB; Wortman BG; Nijman HW; Bosse T; Creutzberg CL
    Int J Gynecol Cancer; 2020 Dec; 30(12):2002-2007. PubMed ID: 33046573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial.
    de Boer SM; Powell ME; Mileshkin L; Katsaros D; Bessette P; Haie-Meder C; Ottevanger PB; Ledermann JA; Khaw P; Colombo A; Fyles A; Baron MH; Jürgenliemk-Schulz IM; Kitchener HC; Nijman HW; Wilson G; Brooks S; Carinelli S; Provencher D; Hanzen C; Lutgens LCHW; Smit VTHBM; Singh N; Do V; D'Amico R; Nout RA; Feeney A; Verhoeven-Adema KW; Putter H; Creutzberg CL;
    Lancet Oncol; 2018 Mar; 19(3):295-309. PubMed ID: 29449189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histopathological features of endometrial carcinomas associated with POLE mutations: implications for decisions about adjuvant therapy.
    Bakhsh S; Kinloch M; Hoang LN; Soslow RA; Köbel M; Lee CH; McAlpine JN; McConechy MK; Gilks CB
    Histopathology; 2016 May; 68(6):916-24. PubMed ID: 26416160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The brave new world of endometrial cancer : Future implications for adjuvant treatment decisions.
    Marnitz S; Waltar T; Köhler C; Mustea A; Schömig-Markiefka B
    Strahlenther Onkol; 2020 Nov; 196(11):963-972. PubMed ID: 32430662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SEOM clinical guidelines for endometrial cancer (2017).
    Santaballa A; Matías-Guiu X; Redondo A; Carballo N; Gil M; Gómez C; Gorostidi M; Gutierrez M; Gónzalez-Martín A
    Clin Transl Oncol; 2018 Jan; 20(1):29-37. PubMed ID: 29238915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High risk endometrial cancer: Clues towards a revision of the therapeutic paradigm.
    Bendifallah S; Ilenko A; Daraï E
    J Gynecol Obstet Hum Reprod; 2019 Dec; 48(10):863-871. PubMed ID: 31176047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of adjuvant therapy in stage IIIC2 endometrial cancer.
    Bogani G; Cappuccio S; Casarin J; Narasimhulu DMM; Cilby WA; Glaser GE; Weaver AL; McGree ME; Keeney GL; Weroha J; Petersen IA; Mariani A
    Int J Gynecol Cancer; 2020 Aug; 30(8):1169-1176. PubMed ID: 32646864
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The immunologic tumor microenvironment in endometrioid endometrial cancer in the morphomolecular context: mutual correlations and prognostic impact depending on molecular alterations.
    Willvonseder B; Stögbauer F; Steiger K; Jesinghaus M; Kuhn PH; Brambs C; Engel J; Bronger H; Schmidt GP; Haller B; Weichert W; Keller G; Noske A; Pfarr N; Boxberg M
    Cancer Immunol Immunother; 2021 Jun; 70(6):1679-1689. PubMed ID: 33340331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Classification of Endometrial Carcinoma: New Perspectives Beyond Morphology.
    Akhtar M; Al Hyassat S; Elaiwy O; Rashid S; Al-Nabet ADMH
    Adv Anat Pathol; 2019 Nov; 26(6):421-427. PubMed ID: 31567131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequencing chemotherapy before radiotherapy for women with stage IIIC endometrial cancer.
    Narasimhulu DM; Block MS; Weaver AL; McGree M; Kumar A; Langstraat C; Petersen I; Mariani A; Glaser G
    Int J Gynecol Cancer; 2021 May; 31(5):702-708. PubMed ID: 33771845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of
    Beinse G; Rance B; Just PA; Izac B; Letourneur F; Saidu NEB; Chouzenoux S; Nicco C; Goldwasser F; Batteux F; Durdux C; Chapron C; Pasmant E; Leroy K; Alexandre J; Borghese B
    Int J Gynecol Cancer; 2020 May; 30(5):640-647. PubMed ID: 32169874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-grade endometrial carcinomas: Morphologic spectrum and molecular classification.
    Zhang C; Zheng W
    Semin Diagn Pathol; 2022 May; 39(3):176-186. PubMed ID: 34852949
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.